Aim: Cancer pain impairs not only physical functions but also social functions and roles. Consequently, the overall health-related quality of life of patients with cancer pain deteriorates. Opioid analgesics are recommended for treating moderate to strong cancer pain. Advances in human genome research have fueled a growing interest to understand individual differences in responsiveness to opioid analgesics.
| INTRODUCTION
Pain is one of the most frequent symptoms among patients with terminal cancer, and the pain-associated distress experienced by those with cancer pain can cause anxiety, depression, and changes in social functions. Indeed, not only physical functions but also social functions and roles have been found to be lower in patients with cancer pain than in the general population; as a result, their overall health and quality of life (QOL) are severely impaired. 1 As anticancer treatments (ie, chemotherapy, radiotherapy, and surgery) become aggressive, the time patients spend with advanced stage disease increases; thus, the treatment of cancer pain is a chronic process. In addition to the advanced and terminal cancer periods in which the prevalence rate of cancer pain is 64%, pain has been reported in 33% of patients just after curative treatment and 59%
of patients during anticancer treatment. 2 However, apart from patients with cancer who are terminally ill, sufficient analgesic supplementation is still not provided to more than half of patients with cancer who have received and just completed anticancer treatment. 3 A systematic review on barriers hindering adequate cancer pain management revealed inadequate assessment of pain and pain management as well as inadequate knowledge of pain management of healthcare professionals. 4 In particular, inadequate knowledge of opioid analgesics (eg, effective dose, upper limits, and the likelihood of addiction or tolerance) has been reported by many physicians and nurses.
Anecdotal variation in opioid analgesia seems to be a likely factor contributing to inadequate pain management. Some variations can be explained by genetic predisposition affecting either pain perception/processing or analgesic responses. 5 For example, among genetic polymorphisms associated with altered pain perception and processing, a mu-opioid receptor single nucleotide polymorphism (SNP)
[OPRM1 118A>G (rs1799971)] has been shown to be associated with a 0.8-fold decrease in pressure pain intensity among carriers. 6 A previous study on OPRM1 118A>G has demonstrated the association between genetic polymorphisms and opioid analgesic responsiveness; patients with the minor allele homozygosity were found to require higher morphine doses (more than twofold) to achieve pain control. 7 Associations between human pain-related genotypes and variability in opioid analgesia have been well investigated. 8 Nevertheless, as most previous studies were based on Caucasian populations, this study aimed to explore and identify novel loci for genes predisposing an individual with cancer pain to opioid analgesic responsiveness in a non-Caucasian population. The results of this study will be useful in developing not only potential testing panels for specific patients who require higher opioid doses but also targeted pharmacotherapy for all cancer pain patients.
| METHODS

| Participants
This study was approved by the appropriate institutional review boards of the respective hospitals, and written informed consent was obtained from all participants. The inclusion criteria were as fol- In the first evaluation, 90 patients [age, 58.4 ± 13.4 years (mean ± SD); female, 50; pain duration, 11.2 ± 18.8 months] were enrolled, and 71 of these patients participated in the second evaluation. Therefore, we analyzed these 71 patients in this study.
| Genotyping
Venous blood samples were collected from all of the participants.
Genomic DNA was isolated from peripheral blood lymphocytes using a standard salting-out method. The DNA was whole-genome amplified, fragmented, denatured, and hybridized to a prepared Omni1-Quad BeadChip (Illumina, San Diego, CA, USA), which contained 1 140 419 markers. All 71 patients were genotyped using the Omni1-Quad BeadChip. Normalized bead-intensity data obtained for each sample were loaded into GenomeStudio software (Genotyping module ver. 1.8.4; Illumina), which converted fluorescence intensities into SNP genotypes. We excluded SNPs with a call rate of less than 95%, with a deviation from Hardy-Weinberg equilibrium at an error level of less than 10 −3 and with a minor allele frequency less than
, which resulted in 771 433 SNPs.
| Statistical analysis of individual genotype data
Statistical calculations for individual genotyping data were performed using plink version 1.07, 9 R package version 2.14. as covariates, because to our best knowledge, no evidence was confirmed that neither pain duration nor opioid duration affects opioid analgesic responsiveness in cancer pain patients. Possibly not to obtain a significant statistical result by chance alone (false-positive results), we set the genomewide significance (ie, P < 5E-8).
Through a genomewide association study (GWAS), we identified the loci for genes predisposing an individual to opioid analgesic responsiveness (ie, pain decrease corresponding to increased opioid analgesics). Then, we analyzed the associations between three variables (genotypes, decreases in pain intensity, and opioid-induced complications) and increased and total opioid dosages using the Kruskal-Wallis test. Bonferroni test was performed for post hoc analysis.
The criterion for significance was set at P < 0.05. In addition, linkage disequilibrium patterns of the relevant SNPs were plotted using Haploview, 11 and the locus zoom around the relevant SNPs was demonstrated by LocusZoom version 1.1, 12 as supplementary figures.
| RESULTS
We conducted a GWAS by evaluating the association between SNPs and opioid analgesic responsiveness. Table 1 shows the characteristics of participants with cancer pain. Figure 1 shows the distribution of the P values of each SNP for all chromosomes (Manhattan plot).
Two SNPs passed the genomewide significance (P = 5E-8) in the additive model, but no SNPs were found under both dominant and recessive models. One SNP (rs1641025, P < 0.0204 × 10 
| DISCUSSION
The present exploratory investigation was, to our best knowledge, the first GWAS to investigate possible associations between SNPs and responsiveness to opioid analgesics for cancer pain in a nonCaucasian population. This exploratory study revealed the associations of the rs1641025 SNP (located on the ABAT gene encoding GABA transaminase) and rs12494691 SNP (which was not associated with any known genes). Our results preliminarily suggest that both SNPs might be potential candidate loci for responsiveness to opioid analgesics, and GABA transaminase might be a possible target for developing adjuvant pharmacotherapy with opioid analgesics.
The prevailing principle for cancer pain treatment is the World Health Organization (WHO) three-step analgesic ladder, and strong opioids are recommended as the most potent analgesics for moderate YOKOSHIMA ET AL.
| 177 to severe pain. 13 However, in clinical practice, it is sometimes difficult to titrate opioid analgesics to achieve pain relief, possibly resulted by inadequate analgesic prescription relative to the pain level. 4 Figure S2 ), which is known to relate with infertility. 15 Therefore, the rs12494691 SNP does not seem to have any associations with adjuvant analgesics for cancer pain at present. On the other hand, the rs1641025 SNP was located in the exonic region of the ABAT gene encoding GABA transaminase. GABA is the most abundant inhibitory neurotransmitter in the central nervous system, where it regulates many physiological functions including somatosensory and pain perception, anxiety, and reward-related processes. In the synapse, its action is mediated through GABA-specific receptors on postsynaptic membranes. GABA is degraded to succinic semialdehyde by GABA transaminase, consequently deactivating GABAergic transmission. Hence, GABA transaminase can modulate GABAergic transmission in the central nervous system. For example, independently of rs1641025, genetic variants of the ABAT gene are likely associated with somatosensory evoked potentials in families at high risk for affective disorders and autism. 16, 17 In terms of GABAergic analgesia, GABAergic agonists themselves are classically known to have analgesic potency, and those can enhance opioid analgesia and attenuate opioid-related adverse effects. 18 Furthermore, the inhibition of GABA transaminase in the spinal cord can lead to antinociception and the potentiation of opioid analgesia. 19 In the periaqueductal gray region of the midbrain, opioids inhibit GABAergic interneurons, which tonically suppress the descending pain inhibitory system, and subsequently exert opioid analgesia. GABA transaminase inhibition in the midbrain can aggravate pain perception. 20 Although we did not T A B L E 1 Characteristics of participants with cancer pain treated with opioid analgesics The Kruskal-Wallis test revealed significant differences among the three groups (major allele homozygosity, heterozygosity, and minor allele homozygosity). Bonferroni post hoc tests were also conducted to examine associations (represented by P values) the other SNP are potential candidate markers for responsiveness to opioid analgesics for cancer pain, and GABA transaminase might be a suitable marker for concomitant use with opioids in adjuvant pharmacotherapy.
